We are live on ! Find out more
GRCL

Gracell Biotechnologies Inc. American Depositary Shares

Delisted

GRCL was delisted on the 21st of February, 2024.

34 hedge funds and large institutions have $450M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more capital invested

Capital invested by funds: $270M → $450M (+$180M)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

17.32% more ownership

Funds ownership: 30.76%48.08% (+17%)

6% more funds holding

Funds holding: 3234 (+2)

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

Holders
34
Holders Change
+2
Holders Change %
+6.25%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
8
Reduced
12
Closed
6
Calls
Puts
Net Calls
Net Calls Change

GRCL Hedge Fund Activity: Q3 2021 in Review

34 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q3 2021, worth a combined $450M — up 67% from $270M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new GRCL positions and 6 closed out — a net gain of 2 holders — while 8 added to existing stakes and 12 trimmed.

The largest buyer was Temasek Holdings, adding an estimated $114M. The largest seller was Vivo Capital, cutting an estimated $4.33M.

  • 34 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q3 2021, up from 32 in Q2 2021.
  • Funds reported $450M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q3 2021, up 67% quarter-over-quarter.
  • 8 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q3 2021 and 6 closed out, a net change of +2 holders.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q3 2021 was Temasek Holdings, an estimated $114M added.
  • The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q3 2021 was Vivo Capital, an estimated $4.33M sold.

Based on aggregated 13F filings for Q3 2021.